Disease
|
Drug/Important Bio-Agent (IBA)
| 1 | CytokinesIBA
01/2024 |
| 1 | Chemokine ReceptorsIBA
01/2024 |
| 1 | Dasatinib (BMS 354825)FDA Link
12/2023 |
| 1 | Phosphotransferases (Kinase)IBA
12/2023 |
| 1 | Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
12/2023 |
| 1 | Glycerol (Glycerine)FDA LinkGeneric
01/2023 |
| 1 | SteroidsIBA
11/2022 |
| 1 | Programmed Cell Death 1 ReceptorIBA
02/2022 |
| 1 | Immune Checkpoint InhibitorsIBA
02/2022 |
| 1 | Glutamic Acid (Glutamate)FDA Link
02/2022 |
| 1 | LuciferasesIBA
02/2022 |
| 1 | Indicators and Reagents (Reagents)IBA
01/2022 |
| 1 | DNA (Deoxyribonucleic Acid)IBA
01/2022 |
| 1 | Cyclin-Dependent Kinases (cdk Proteins)IBA
09/2021 |
| 1 | Enhancer of Zeste Homolog 2 ProteinIBA
09/2021 |
| 1 | Histone MethyltransferasesIBA
09/2021 |
| 1 | Cyclin D1IBA
09/2021 |
| 1 | 14- methyl- 20- oxa- 5,7,14,26- tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8(27),9,11,16,21,23- decaeneIBA
09/2021 |
| 1 | Reactive Oxygen Species (Oxygen Radicals)IBA
02/2021 |
| 1 | AntioxidantsIBA
02/2021 |
| 1 | Therapeutic UsesIBA
01/2021 |
| 1 | AntigensIBA
04/2019 |
| 1 | Peroxidase (Myeloperoxidase)IBA
02/2014 |
| 1 | CholesterolIBA
02/2014 |
| 1 | LipidsIBA
02/2014 |
| 1 | Proteins (Proteins, Gene)FDA Link
02/2014 |
| 1 | HDL LipoproteinsIBA
02/2014 |
| 1 | Apolipoprotein A-I (Apolipoprotein A1)IBA
02/2014 |
| 1 | Tumor Biomarkers (Tumor Markers)IBA
01/2012 |
| 1 | Prostate-Specific Antigen (Semenogelase)IBA
10/2007 |
|
Therapy/Procedure
|